GlassScriptPhysician profile
Maxwell Janosky
NPI 1972739308
$19,135.07
in general payments reported to CMS, 2019-2025
69 companies · $2,948 in 2025
The $2,948 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,989 · 2020: $2,683 · 2021: $1,782 · 2022: $2,042 · 2023: $2,520 · 2024: $3,171 · 2025: $2,948.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,837 · Consulting Fee: $525 · Education: $277.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,836.53 |
| Consulting Fee | $525.00 |
| Education | $276.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,763.42 | 2019-2025 | Lynparza, Calquence, Tagrisso |
| Tesaro, INC. | $3,704.37 | 2019 | |
| Glaxosmithkline, LLC. | $1,467.57 | 2021-2025 | Jemperli, Zejula, Ojjaara |
| Novartis Pharmaceuticals Corporation | $1,356.15 | 2021-2025 | |
| Daiichi Sankyo INC. | $1,347.67 | 2020-2025 | Enhertu, Injectafer, Vanflyta |
| Merck Sharp & Dohme LLC | $997.87 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Incyte Corporation | $475.17 | 2019-2025 | Jakafi |
| Novocure INC. | $456.06 | 2021-2024 | Optune |
| Janssen Biotech, INC. | $415.70 | 2021-2025 | Rybrevant, Darzalex, Tecvayli |
| E.R. Squibb & Sons, L.L.C. | $405.77 | 2020-2025 | Reblozyl, Opdivo, Opdualag |
| Bayer Healthcare Pharmaceuticals INC. | $390.91 | 2020-2025 | |
| Pfizer INC. | $383.36 | 2020-2025 | |
| Celgene Corporation | $298.05 | 2019-2025 | Reblozyl, Pomalyst |
| Eisai INC. | $274.68 | 2021-2025 | |
| Lilly USA, LLC | $243.91 | 2022-2025 | Verzenio, Jaypirca, Retevmo |
Show all 67 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $177.01 | 2020-2025 | Lumakras, Vectibix, Nplate |
| Genzyme Corporation | $166.57 | 2020-2025 | |
| Seagen INC. | $162.40 | 2021-2023 | Adcetris |
| Janssen Pharmaceuticals, INC | $158.16 | 2022-2024 | Xarelto |
| Astellas Pharma US INC | $152.36 | 2024-2025 | Padcev, Vyloy |
| Alexion Pharmaceuticals, INC. | $147.32 | 2019-2025 | Ultomiris |
| Immunogen, INC. | $136.21 | 2023-2024 | Elahere, Elahere |
| Mirati Therapeutics, INC. | $134.28 | 2023-2024 | Krazati |
| Novo Nordisk INC | $111.11 | 2022 | |
| Abbvie INC. | $109.48 | 2024-2025 | |
| Genentech USA, INC. | $101.29 | 2023-2025 | Polivy, Venclexta, Itovebi |
| Genmab U.S., INC. | $92.77 | 2021-2023 | Tivdak |
| Emd Serono, INC. | $85.89 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $83.08 | 2023-2025 | Libtayo |
| Tempus Ai, INC | $77.96 | 2024-2025 | Xt Cdx |
| Array Biopharma INC | $77.19 | 2022-2025 | Mektovi, Braftovi, Lorbrena |
| Myriad Genetic Laboratories, INC. | $73.05 | 2023-2024 | Precisetumor, Mychoice Cdx |
| Sanofi-Aventis U.S. LLC | $69.99 | 2023 | |
| Stemline Therapeutics INC. | $64.14 | 2025 | Orserdu |
| Pharmaessentia USA Corporation | $57.97 | 2023-2025 | Besremi |
| Takeda Pharmaceuticals U.S.A., INC. | $55.78 | 2024-2025 | Alunbrig, Iclusig, Fruzaqla |
| Exelixis INC. | $55.28 | 2023-2024 | Cabometyx |
| Morphosys, US INC. | $55.09 | 2023 | Monjuvi |
| Tersera Therapeutics LLC | $53.37 | 2025 | Zoladex |
| Pharmacosmos Therapeutics INC. | $51.75 | 2022-2023 | Monoferric |
| Sumitomo Pharma America, INC. | $50.44 | 2023-2025 | Orgovyx |
| Coherus Oncology, INC. | $38.48 | 2022 | |
| Puma Biotechnology, INC. | $37.83 | 2025 | |
| Taiho Oncology, INC. | $37.75 | 2024-2025 | |
| Foundation Medicine, INC. | $36.79 | 2023 | |
| Aveo Pharmaceuticals, INC. | $36.44 | 2024 | |
| Geron Corporation | $33.18 | 2025 | Rytelo |
| Beigene USA, INC. | $31.59 | 2023-2024 | Brukinsa |
| Cti Biopharma Corp. | $27.26 | 2022 | |
| Clovis Oncology, INC. | $26.80 | 2022 | |
| Kite Pharma, INC. | $24.52 | 2020 | |
| Adaptive Biotechnologies Corporation | $21.61 | 2023 | Clonoseq |
| G1 Therapeutics, INC. | $20.82 | 2023 | Cosela |
| Olympus America INC. | $19.49 | 2023 | Olympus |
| Jazz Pharmaceuticals INC. | $18.66 | 2025 | |
| Accord Healthcare, INC. | $17.86 | 2025 | |
| Beone Medicines USA, INC. | $17.06 | 2025 | Brukinsa |
| Aadi Bioscience, INC. | $16.81 | 2024 | Fyarro |
| Veloxis Pharmaceuticals, INC. | $16.77 | 2023 | Envarsus |
| Legend Biotech USA INC. | $16.65 | 2024 | |
| Rigel Pharmaceuticals, INC. | $15.84 | 2022 | |
| Myovant Sciences INC. | $14.59 | 2022 | |
| Alfasigma USA, INC. | $14.36 | 2022 | |
| Telix Pharmaceuticals | $13.57 | 2023 | Illuccix |
| Blueprint Medicines Corporation | $13.32 | 2023 | Ayvakit |
| Pharmacyclics LLC, An Abbvie Company | $13.24 | 2023 | Imbruvica |
| Sun Pharmaceutical Industries INC. | $13.18 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maxwell Janosky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.